Stay updated on Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page’s displayed site revision updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check12 days agoChange DetectedThe study record for a completed Phase 2 pembrolizumab trial in metastatic biliary tract cancer is displayed, with its design, eligibility criteria, outcome measures, and study dates.SummaryDifference37%

- Check19 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with an error screen. This indicates access is blocked and the study information cannot be viewed.SummaryDifference16%

Stay in the know with updates to Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Biliary Tract Cancer Clinical Trial page.